SSG
ADVM

Summit Securities Group’s Adverum Biotechnologies ADVM Stock Holding History

Summit Securities Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-48
Closed -$16K – 593
2014
Q3 		$16K Buy
+48
New +$14.3K ﹤0.01% 506

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Summit Securities Group's ADVM Position: Q4 2014 in Review

Summit Securities Group sold out of Adverum Biotechnologies (ADVM) in Q4 2014, closing a stake of 48 shares — an estimated $16K sold.

Summit Securities Group first reported a position in ADVM in Q3 2014 and held it in 1 quarter. The position peaked at $16K in Q3 2014. 84 funds tracked by Wall St. Rank hold ADVM as of Q4 2014.

  • Summit Securities Group reported no remaining Adverum Biotechnologies position as of Q4 2014 after selling out during the quarter.
  • Summit Securities Group sold 48 Adverum Biotechnologies shares in Q4 2014, an estimated $16K.
  • Summit Securities Group first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 1 quarter.
  • Summit Securities Group's Adverum Biotechnologies position peaked at $16K in Q3 2014.
  • 84 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2014.

Based on Summit Securities Group's 13F filing for Q4 2014, filed 5 Feb 2015.